Aardvark Therapeutics, Inc. (AARD)
NASDAQ: AARD · Real-Time Price · USD
5.22
+0.23 (4.61%)
At close: Oct 5, 2026, 4:00 PM EDT
5.25
+0.03 (0.57%)
After-hours: Oct 5, 2026, 7:30 PM EDT
Aardvark Therapeutics Employees
Aardvark Therapeutics had 28 employees as of June 30, 2026. The number of employees decreased by 3 or -9.68% compared to the same quarter last year.
Employees
28
Change
-3
Growth
-9.68%
Revenue / Employee
n/a
Profits / Employee
-$2,496,036
Market Cap
114.24M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2026 | 28 | -3 | -9.68% | 28 | 0 |
| Mar 31, 2026 | 40 | 14 | 53.85% | 40 | 0 |
| Dec 31, 2025 | 40 | 18 | 81.82% | 40 | 0 |
| Sep 30, 2025 | 33 | 15 | 83.33% | 33 | 0 |
| Jun 30, 2025 | 31 | 17 | 121.43% | 31 | 0 |
| Mar 31, 2025 | 26 | 12 | 85.71% | 26 | 0 |
| Dec 31, 2024 | 22 | - | - | 22 | 0 |
| Sep 30, 2024 | 18 | - | - | 17 | 1 |
| Jun 30, 2024 | 14 | - | - | 12 | 2 |
Related Stocks
| Company Name | Employees |
|---|---|
| LENZ Therapeutics | 152 |
| Inovio Pharmaceuticals | 112 |
| Foghorn Therapeutics | 106 |
| Vivani Medical | 42 |
| Milestone Pharmaceuticals | 38 |
| Corbus Pharmaceuticals Holdings | 36 |
| Genelux | 26 |
| Unicycive Therapeutics | 22 |
AARD News
- 9 hours ago - If You Lost Money Investing in Aardvark Therapeutics, Inc. (AARD) Contact Robbins LLP for Information About Recovering Your Losses - Newsfile Corp
- 3 days ago - Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 days ago - AARD Stock News: Robbins LLP Reminds Aardvark Therapeutics, Inc. Stockholders to Contact the Firm Before the October 13, 2026 Lead Plaintiff Deadline - PRNewsWire
- 11 days ago - SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 13, 2026 in Aardvark Therapeutics, Inc. Lawsuit - AARD - PRNewsWire
- 17 days ago - Lowey Dannenberg, P.C. is Investigating Aardvark Therapeutics, Inc. (NASDAQ: AARD) for Potential Violations of the Federal Securities Laws - GlobeNewsWire
- 18 days ago - Robbins LLP is Investigating Allegations that Aardvark Therapeutics, Inc. Misled Investors Regarding the Viability and Efficacy of its Lead Drug Candidate ARD-101 - Newsfile Corp
- 4 weeks ago - AARD Stockholders Have Rights – If You Lost Money Investing in Aardvark Therapeutics, Inc. Contact Robbins LLP for Information About Recovering Your Losses - Business Wire
- 6 weeks ago - AARDVARK THERAPEUTICS, INC. (AARD) INVESTOR ALERT Investors With Large Losses in Aardvark Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights - Newsfile Corp